DCR-MYC commenced phase I trial in 2014, in which cancer patients (solid tumors, multiple myeloma, Non-Hodgkin’s Lymphoma, and pancreatic neuroendocrine tumors) were enrolled for intravenous treatment of DCR-MYC once a week for two weeks, followed by a drug-free week. This evidence concerns the gene MYC and non-Hodgkin lymphoma.